Eburicoic acid
Based on 1 publication(s) in Google Scholar
Eburicoic acid protects the liver from CCl4-induced hepatic damage via antioxidant and anti-inflammatory mechanisms. And Eburicoic acid has antidiabetic and antihyperlipidemic effects.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.61%
- CAS 番号: 560-66-7
- 分子式: C31H50O3
- 分子量:470.73
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
MedChemExpress(MCE)の使用を引用している文献 Eburicoic acid
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
25 μM
Compound: 3
|
Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
|
[PMID: 15620242] |
| HL-60 | IC50 |
25 μM
Compound: 102
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 23092389] |
| MCF7 | IC50 |
>100 μM
Compound: 21
|
Cytotoxicity against human MCF7 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 24 hrs by MTT assay
|
[PMID: 31891260] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
10 μM
Compound: Eburicoic acid
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| SW480 | IC50 |
>100 μM
Compound: 21
|
Cytotoxicity against human SW480 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human SW480 cells incubated for 24 hrs by MTT assay
|
[PMID: 31891260] |
| U-251 | IC50 |
>100 μM
Compound: 21
|
Cytotoxicity against human U251 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human U251 cells incubated for 24 hrs by MTT assay
|
[PMID: 31891260] |
化学情報
-
CAS 番号 560-66-7
-
性状 Solid
-
分子量 470.73
-
分子式 C31H50O3
-
Color White to off-white
-
SMILES
C[C@]12C3=C(CC[C@@]1([C@@](CC2)([H])[C@H](C(O)=O)CCC(C(C)C)=C)C)[C@@]4([C@@](C(C)([C@H](CC4)O)C)([H])CC3)C
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Med Rep
Eburicoic acid inhibits endothelial cell pyroptosis and retards the development of atherosclerosis through the Keap1/Nrf2/HO‑1/ROS pathway. [Abstract]2025 Jul;32(1):186. PMID: 40314092
溶剤 & 溶解度
体外:
DMSO : 0.5 mg/mL (1.06 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Huang GJ, et al. Hepatoprotective effects of eburicoic acid and dehydroeburicoic acid from Antrodia camphorata in a mouse model of acute hepatic injury. Food Chem. 2013;141(3):3020-3027. [Content Brief]
[2]. Lin CH, et al. Eburicoic Acid, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects in Palmitate-Treated C2C12 Myotubes and in High-Fat Diet-Fed Mice. Int J Mol Sci. 2017;18(11):2314. Published 2017 Nov 2. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1244 mL | 10.6218 mL | 21.2436 mL | 53.1090 mL |